Johnson & Johnson Exits Biotech Partnerships, Retains Stakes in Acquisition Targets

viernes, 27 de marzo de 2026, 12:49 am ET1 min de lectura
ARWR--
JNJ--
PHGE--

Johnson & Johnson has exited three biotechs, including Arrowhead Pharmaceuticals and BiomX, while retaining stakes in several rumored acquisition targets. The company sold 247,598 shares in Arrowhead and 96,866 shares in BiomX. Johnson & Johnson's Innovative Medicine division, formerly Janssen unit, had previously collaborated with both companies.

Johnson & Johnson Exits Biotech Partnerships, Retains Stakes in Acquisition Targets

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios